Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1827)	3/2/2002 8:39:52 PM
From: arnie h	Respond to of 10345

From American Home Products' website - >AHP and Elan have formed one of the broadest research alliances in the pharmaceutical industry to develop immunotherapeutic approaches to treat and prevent Alzheimer's disease. AN-1792 represents the first in a series of therapeutic approaches currently under development within this collaboration that explore the clinical potential of immunotherapy for Alzheimer’s disease. Elan and Wyeth are committed to further research and to finding a cure for Alzheimer's disease, an affliction that claims millions of lives each year. “These developments are not uncommon in early clinical research with an innovative compound like AN-1792,” says L. Patrick Gage, President, Wyeth-Ayerst Research. “Our immediate goals are two-fold – the safety of all patients involved in these trials; and to gain a greater understanding of the nature of these events. Both companies are committed to developing a treatment for Alzheimer’s disease and we are hopeful that our alternative Alzheimer’s approaches will continue to advance in development.” >